Literature DB >> 8273585

Inhibition of endotoxin-induced hypothermia and serum TNF-alpha levels in CD-1 mice by various pharmacological agents.

S J Ochalski1, D A Hartman, M T Belfast, T L Walter, K B Glaser, R P Carlson.   

Abstract

Intraperitoneal injection of lipopolysaccharide (LPS) was used to elicit a sublethal, shock-like condition in mice. LPS, 2.5 mg/kg i.p., induced hypothermia, elevated serum TNF-alpha levels and lethality over a 48 h period in male CD-1 mice. The 5-lipoxygenase (LO) inhibitors, WY-50,295 tromethamine and zileuton (100 mg/kg p.o), significantly inhibited hypothermia at 4, 24 and 48 h after LPS. Interestingly, whereas cyclooxygenase (CO) inhibitors (ibuprofen, etodolac, naproxen and tenidap) at 40-80 mg/kg p.o. stimulated hypothermia at 4 h, they significantly reduced the later stages of hypothermia at 24-48 h. Rolipram (PDE-IV inhibitor) and dexamethasone significantly reduced hypothermia at 4-24 h and 1-24 h, respectively. All the anti-inflammatory agents significantly reduced elevated TNF-alpha levels at approximately 70 min post-LPS, except for ibuprofen. In conclusion, these anti-inflammatory standards indicate that LPS-induced shock involves multiple lipid mediators (PG's, LT's and possibly PAF) and secondary cytokine generation. This sublethal model of LPS-induced shock represents a sensitive model for estimating the efficacy of potential drug candidates for the treatment of endotoxic shock.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8273585     DOI: 10.1007/bf01972718

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  8 in total

1.  Time course of various inflammatory mediators during recurrent endotoxemia.

Authors:  B Klosterhalfen; K Hörstmann-Jungemann; P Vogel; S Flohé; F Offner; C J Kirkpatrick; P C Heinrich
Journal:  Biochem Pharmacol       Date:  1992-05-28       Impact factor: 5.858

2.  Significance of lipid mediators in shock states.

Authors:  A M Lefer
Journal:  Circ Shock       Date:  1989-01

3.  Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice.

Authors:  A K Myers; J W Robey; R M Price
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

Review 4.  Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.

Authors:  H A Ball; J A Cook; W C Wise; P V Halushka
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

5.  IL-8 in septic shock, endotoxemia, and after IL-1 administration.

Authors:  K J Van Zee; L E DeForge; E Fischer; M A Marano; J S Kenney; D G Remick; S F Lowry; L L Moldawer
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

6.  Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies.

Authors:  L E DeForge; J S Kenney; M L Jones; J S Warren; D G Remick
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

7.  Lipoxygenase and cyclooxygenase blockade by BW755C prevents endotoxin-induced hypotension but not changes in glucose metabolism.

Authors:  C H Lang; H L Blakesley; G J Bagby; J J Spitzer
Journal:  Horm Metab Res       Date:  1988-09       Impact factor: 2.936

8.  Detection of circulating tumor necrosis factor after endotoxin administration.

Authors:  H R Michie; K R Manogue; D R Spriggs; A Revhaug; S O'Dwyer; C A Dinarello; A Cerami; S M Wolff; D W Wilmore
Journal:  N Engl J Med       Date:  1988-06-09       Impact factor: 91.245

  8 in total
  7 in total

1.  Acute Administration of the Nonpathogenic, Saprophytic Bacterium, Mycobacterium vaccae, Induces Activation of Serotonergic Neurons in the Dorsal Raphe Nucleus and Antidepressant-Like Behavior in Association with Mild Hypothermia.

Authors:  Philip H Siebler; Jared D Heinze; Drake M Kienzle; Matthew W Hale; Jodi L Lukkes; Nina C Donner; Jared M Kopelman; Orlando A Rodriguez; Christopher A Lowry
Journal:  Cell Mol Neurobiol       Date:  2017-11-13       Impact factor: 5.046

2.  Food deprivation alters thermoregulatory responses to lipopolysaccharide by enhancing cryogenic inflammatory signaling via prostaglandin D2.

Authors:  Catherine M Krall; Xiujuan Yao; Martha A Hass; Carlos Feleder; Alexandre A Steiner
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-04-14       Impact factor: 3.619

3.  Discovery of Nitro-azolo[1,5-a]pyrimidines with Anti-Inflammatory and Protective Activity against LPS-Induced Acute Lung Injury.

Authors:  Alexander Spasov; Vadim Kosolapov; Denis Babkov; Vladlen Klochkov; Elena Sokolova; Mikhail Miroshnikov; Alexander Borisov; Yulia Velikorodnaya; Alexey Smirnov; Konstantin Savateev; Victor Fedotov; Svetlana Kotovskaya; Vladimir Rusinov
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

4.  Upregulation of B1 receptor mediating des-Arg9-BK-induced rat paw oedema by systemic treatment with bacterial endotoxin.

Authors:  M M Campos; G E Souza; J B Calixto
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

5.  Possible therapeutic effect of trilostane in rodent models of inflammation and nociception.

Authors:  David Tung; John Ciallella; Heather Hain; Peter H Cheung; Saurabh Saha
Journal:  Curr Ther Res Clin Exp       Date:  2013-12

6.  Body temperature measurement in mice during acute illness: implantable temperature transponder versus surface infrared thermometry.

Authors:  Jie Mei; Nico Riedel; Ulrike Grittner; Matthias Endres; Stefanie Banneke; Julius Valentin Emmrich
Journal:  Sci Rep       Date:  2018-02-23       Impact factor: 4.379

7.  In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis.

Authors:  Athina Theodoridou; Helen Gika; Eudoxia Diza; Alexandros Garyfallos; Loucas Settas
Journal:  Mediterr J Rheumatol       Date:  2017-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.